4basebio’s (4BB) “Outperform” Rating Reiterated at Royal Bank Of Canada

Royal Bank Of Canada restated their outperform rating on shares of 4basebio (LON:4BB) in a research report report published on Thursday morning, Marketbeat Ratings reports. They currently have a GBX 1,600 price target on the stock.

4basebio Stock Down 3.2%

4BB stock opened at GBX 750.50 on Thursday. The stock has a fifty day moving average of GBX 868.70 and a 200-day moving average of GBX 1,006.25. 4basebio has a fifty-two week low of GBX 704.50 and a fifty-two week high of GBX 1,500. The company has a debt-to-equity ratio of 201.47, a quick ratio of 3.52 and a current ratio of 2.73. The company has a market capitalization of £116.21 million, a price-to-earnings ratio of -798.40 and a beta of 1.09.

4basebio (LON:4BB) last posted its quarterly earnings data on Monday, September 29th. The company reported GBX (50) earnings per share for the quarter. As a group, equities research analysts predict that 4basebio will post -3.43 earnings per share for the current year.

Insider Activity

In related news, insider Heikki Lanckriet bought 2,000 shares of the stock in a transaction that occurred on Monday, September 29th. The stock was bought at an average cost of GBX 749 per share, for a total transaction of £14,980. Insiders own 12.02% of the company’s stock.

About 4basebio

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients.